The primary purpose of this study was to test the efficacy of two SSTR2 antagonists in a rodent model of T2D to see if treatment could enhance the endogenous glucagon counterregulatory response and prevent hypoglycemia during an insulin-induced hypoglycemic challenge. This evidence concerns the gene GCG and type 2 diabetes mellitus.